Enabling Large-Scale GMP-ready Peptide Production with a new, reliable and cost-efficient Bioprocess

Informations projet

NUMA-SCALE

N° de convention de subvention: 836885

DOI

10.3030/836885

Projet clôturé

Date de signature de la CE 29 Novembre 2018

Date de début 1 Novembre 2018

Date de fin 28 Février 2019

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

NUMAFERM GMBH
Germany

Periodic Reporting for period 1 - NUMA-SCALE (Enabling Large-Scale GMP-ready Peptide Production with a new, reliable and cost-efficient Bioprocess)

Période du rapport: 2018-11-01 au 2019-02-28

Résumé du contexte et des objectifs généraux du projet

Peptide therapeutics are progressively gaining the attention of Pharma and Biotech companies as they possess desirable pharmacological profiles and their specificity translates into outstanding safety, tolerability, low toxicity and efficacy profiles in humans, in contrast to traditional small molecules. With the increase of approved peptide-based drugs, the production of peptides will escalate but peptide manufacturing companies face a several challenges in their production processes, (e.g. high production costs and bad scalability) which results in shortages of peptide APIs in the market.
Numaferm is a German company, focus on making peptide production more cost-efficient and sustainable for the pharmaceutical market. We have developed an innovative bio-based process for peptide production that copes with the challenges of the current peptide production methods. It consists of 2 patented technologies, NUMAtag and NUMAswitch, whose unique features are: cost-efficient production (50x manufacturing costs reduction); sustainability (reduced carbon foot print by >90%) and scalability (ton scale, no peptide length limitation).
Currently, we produce peptides as APIs for customers at discovery and pre-clinical stages (max. 1gr, research grade) and through the Numa-Scale project we aim to evolve to next stage (i.e. clinical development, 250gr scale, GMP grade).

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Our key achievements include: technical development of our innovative processes, implementation of the first customer projects and patent application and granting.
In this feasibility study we have analyzed our core-technologies and identified the technical improvements necessary to upscale our production, work on the quality requirements for pharma industry and extend our commercial capabilities. Besides, to assess the commercial feasibility of our project we conducted an in-depth analysis of the peptide therapeutics market (its dynamics, environment, target customers, competitors, barriers and mitigation measures), and we have also updated the FTO analysis.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Our value proposition to Pharma and Biotech companies (our customers) includes: Scalability (up to ton scale), no peptide length limitation (accessibility to large peptides), high peptide purity (over 99%) and reduction on R&D time due to shorter production times (6 months vs 1-3 years).
The Numa-Scale project will have a positive impact on economy and society as it will result in more affordable and accessible treatments for numerous diseases.

image-1.png